- Conditions
- Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
- Interventions
- Infigratinib, Placebo
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced May 21, 2026, 11:10 PM EDT